 CytoDyn Inc has announced a study for treating triple-negative breast cancer TNBC with its flagship drug leronlimab in a humanized TNBC xenograft model. The late-stage biotechnology company said the investigator-initiated study is being led by Dr Jangsoon Lee, assistant professor of Breast Medical Oncology Research at The University of Texas MD Anderson Cancer Center. 